{
    "clinical_study": {
        "@rank": "97669", 
        "brief_summary": {
            "textblock": "To provide oral sorivudine ( BV-araU ) to pediatric HIV-infected patients with\n      varicella-zoster viral disease who have failed or are intolerant of alternative therapy."
        }, 
        "brief_title": "A Study of BV-araU in the Treatment of Varicella-Zoster Viral Disease (VZV) in HIV-Infected Children Who Have Not Had Success With or Who Cannot Take Other Treatments for VZV", 
        "condition": [
            "HIV Infections", 
            "Chickenpox"
        ], 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome", 
                "Chickenpox", 
                "Herpes Zoster", 
                "Virus Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "Any physician qualified to treat pediatric AIDS patients may enroll patients in this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  HIV infection.\n\n          -  Cutaneous, visceral, or ocular varicella-zoster viral infection.\n\n          -  Refractory or intolerant to acyclovir or foscarnet therapy.\n\n          -  Consent of parent or guardian.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Inability to take oral capsules or tolerate liquids.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  5-flucytosine, 5-fluorouracil, high-dose prednisone, or probenecid.\n\n        Patients with the following prior condition are excluded:\n\n        History of immediate hypersensitivity to nucleoside analogues.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  5-flucytosine, 5-fluorouracil, high-dose prednisone, or probenecid within 4 weeks\n             prior to study entry.\n\n        Required:\n\n          -  Prior acyclovir or foscarnet."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "2 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "id_info": {
            "nct_id": "NCT00002358", 
            "org_study_id": "255A", 
            "secondary_id": "AI458-903"
        }, 
        "intervention": {
            "intervention_name": "Sorivudine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Sorivudine"
        }, 
        "keyword": [
            "Herpes Zoster", 
            "Acquired Immunodeficiency Syndrome", 
            "AIDS-Related Complex", 
            "Antiviral Agents", 
            "sorivudine", 
            "Chickenpox"
        ], 
        "lastchanged_date": "October 1, 2007", 
        "link": [
            {
                "description": "BMS Clinical Trials Disclosure", 
                "url": "http://ctr.bms.com/ctd/start.do"
            }, 
            {
                "description": "For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm", 
                "url": "http://www.fda.gov/MEDWATCH/safety.htm"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Wallingford", 
                    "country": "United States", 
                    "state": "Connecticut", 
                    "zip": "06492"
                }, 
                "name": "Bristol - Myers Squibb Co"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Open-Label BV-araU Treatment of Pediatric HIV-Infected Patients With Cutaneous, Visceral, or Ocular Varicella-Zoster Viral Disease Who Have Failed or Are Intolerant of Standard Therapy", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002358"
        }, 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Efficacy Study, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2007"
    }, 
    "geocoordinates": {
        "Bristol - Myers Squibb Co": "41.457 -72.823"
    }
}